Fresenius Kabi USA, LLC recalled 2,199,850 vials of Famotidine Injection on November 6, 2025. The recall follows reports of microbial contamination and endotoxin testing failures. Healthcare providers and consumers should stop using this product immediately.
Microbial Contamination of Sterile Products; out of limit results obtained for endotoxin testing.
Consumers and healthcare providers should stop using this product immediately. Contact Fresenius Kabi USA, LLC or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall includes Famotidine Injection, USP, 20 mg per 2 mL, sold in 2 mL vials. The recalled lot numbers are 6133156, 6133194, and 6133388, with expiration dates of August 2026 and October 2026.
The product poses a high risk due to microbial contamination. This contamination can lead to serious infections, especially in immunocompromised patients.
No specific incidents of illness have been reported. The recall is precautionary, stemming from out-of-limit results obtained during endotoxin testing.
Stop using Famotidine Injection immediately. Contact Fresenius Kabi USA, LLC or your healthcare provider for further guidance.
For questions, call Fresenius Kabi USA, LLC at 1-800-XXX-XXXX or visit their website at www.fresenius-kabi.com.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.